A Phase 1b/2, Open-label, Multicenter Dose-ranging Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SRA737 in Combination With Niraparib in Subjects With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 13 Jul 2020
At a glance
- Drugs Niraparib (Primary) ; SRA 737 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sierra Oncology
- 13 Jul 2020 Status changed from recruiting to discontinued.
- 20 May 2019 Status changed from planning to recruiting.
- 28 Feb 2019 According to a Sierra Oncology Inc. media release, the company is currently evaluating the optimal timing to commence this trial.